ZD6474

TRIAL 62 HNSCC
AN OPEN LABEL, PHASE I STUDY TO ASSESS THE MAXIMUM TOLERATED DOSE OF ZD6474 (ZACTIMA^TM) GIVEN CONCOMITANTLY WITH RADIATION THERAPY OR CONCOMITANTLY WITH WEEKLY CISPLATIN CHEMOTHERAPY AND RADIATION THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, UNRESECTED, STAGE III-IV HEAD AND NECK SQUAMOUS CELL CARCINOMA